Literature DB >> 18565368

Vital pulp therapy with new materials: new directions and treatment perspectives--permanent teeth.

David E Witherspoon1.   

Abstract

Pulp necrosis in immature teeth subsequent to caries has a major impact on long-term tooth retention. The aim of vital pulp therapy is to maintain pulp viability by eliminating bacteria from the dentin-pulp complex and to establish an environment in which apexogenesis can occur. A complicating factor in treating immature teeth is the difficulty predicting the degree of pulpal damage. The ability of the clinician to manage the health of the remaining pulpal tissue during the procedure is paramount. Currently, the best method appears to be the ability to control pulpal hemorrhage by using sodium hypochlorite. Mineral trioxide aggregate (MTA) currently is the optimum material for use in vital pulp therapy. Compared with the traditional material of calcium hydroxide, it has superior long-term sealing ability and stimulates a higher quality and greater amount of reparative dentin. In the medium-term clinical assessment, it has demonstrated a high success rate. Thus, MTA is a good substitute for calcium hydroxide in vital pulp procedures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565368     DOI: 10.1016/j.joen.2008.02.030

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  32 in total

1.  The Effect of Low Level Laser Therapy on Direct Pulp Capping in Dogs.

Authors:  Maryam Bidar; Siavash Moushekhian; Maryam Gharechahi; Ali Talati; Farzaneh Ahrari; Maryam Bojarpour
Journal:  J Lasers Med Sci       Date:  2016-07-18

2.  How does the pulpal response to Biodentine and ProRoot mineral trioxide aggregate compare in the laboratory and clinic?

Authors:  R Careddu; H F Duncan
Journal:  Br Dent J       Date:  2018-10-19       Impact factor: 1.626

3.  Five-year results of vital pulp therapy in permanent molars with irreversible pulpitis: a non-inferiority multicenter randomized clinical trial.

Authors:  Saeed Asgary; Mohammad Jafar Eghbal; Mahta Fazlyab; Alireza Akbarzadeh Baghban; Jamileh Ghoddusi
Journal:  Clin Oral Investig       Date:  2014-04-27       Impact factor: 3.573

Review 4.  Mineral trioxide aggregate (MTA): its history, composition, and clinical applications.

Authors:  Peter Z Tawil; Derek J Duggan; Johnah C Galicia
Journal:  Compend Contin Educ Dent       Date:  2015-04

5.  A survey of dental practitioners in Wales to evaluate the management of deep carious lesions with vital pulp therapy in permanent teeth.

Authors:  J S Chin; M B Thomas; M Locke; P M H Dummer
Journal:  Br Dent J       Date:  2016-09-23       Impact factor: 1.626

6.  [Vital pulp therapy of damaged dental pulp].

Authors:  Zhou Xuedong; Huang Dingming; Liu Jianguo; Huang Zhengwei; Wei Xin; Yang Deqin; Zhao Jin; Chen Liming; Zhu Lin; Li Yanhong; Li Jiyao
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-08-01

7.  MTA versus Biodentine: Review of Literature with a Comparative Analysis.

Authors:  Mandeep Kaur; Harpreet Singh; Jaidev Singh Dhillon; Munish Batra; Meenu Saini
Journal:  J Clin Diagn Res       Date:  2017-08-01

8.  Mineral trioxide aggregate promotes odontoblastic differentiation via mitogen-activated protein kinase pathway in human dental pulp stem cells.

Authors:  Xiu Zhao; Wenxi He; Zhi Song; Zhongchun Tong; Shiting Li; Longxing Ni
Journal:  Mol Biol Rep       Date:  2011-05-11       Impact factor: 2.316

9.  Reparative dentinogenesis induced by mineral trioxide aggregate: a review from the biological and physicochemical points of view.

Authors:  Takashi Okiji; Kunihiko Yoshiba
Journal:  Int J Dent       Date:  2009-12-28

10.  Effect of indomethacin-loaded nanocapsules incorporation in a dentin adhesive resin.

Authors:  Bruna Genari; Vicente Castelo Branco Leitune; Denise Soledade Jornada; Melissa Camassola; Adriana Raffin Pohlmann; Sílvia Stanisçuaski Guterres; Susana Maria Werner Samuel; Fabrício Mezzomo Collares
Journal:  Clin Oral Investig       Date:  2016-04-12       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.